FEED Company Profile and Key Details

ENvue Medical, Inc. generated EPS of -$96.17 over the past year. Five-year average earnings growth is 40.47%.

FEED has shown weak momentum, losing -46.05% over the past week and -79.06% over the past quarter, though year-to-date performance is down -46.75%. Short-term trend indicators are mixed aligned (SMA20 -19.42%, SMA50 -8.7%, SMA200 -65.65%). The stock’s 14-day RSI is 44.95 (neutral), while the ATR of 0.55 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -98.61% below its high and over 128.28% above its low. Average 10-day trading volume of 1.22 million shares is below the 3-month average of 3.15 million, indicating normal recent market interest.

Dividend and splits history remains an important factor for investors monitoring long-term returns.

ENvue Medical, Inc. (NASDAQ:FEED) closed at $1.09 USD, losing -$0.03 (-3.10%) from the previous close of $1.13. The stock is currently mid-range between its 52-week high and low $1.00 and $5.98. With a market capitalization of about $1.20 million, ENvue Medical, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~1.59). Headquartered in Arlington Heights, IL, ENvue Medical, Inc. operates in the Healthcare sector and the Medical - Specialties industry. Led by CEO Doron Robert Besser, the company employs approximately 31 people and listed since December 12, 2025. NanoVibronix, Inc. engages in the development of noninvasive biological response-activating devices.

ENvue Medical, Inc. trades at a P/E ratio of -0.06, slightly below the S&P 500 average, with a price-to-sales ratio of 0.47 and a price-to-book ratio of 0.03 suggesting the stock is closer to book value. The P/FCF stands at -0.13, also above market averages.

ENvue Medical, Inc. (NASDAQ:FEED) shares are down -46.75% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows ENvue Medical, Inc. trading at a premium to the broader market with a P/E of -0.06. Our AI forecast model points to short-term weakness (-27.27% over two weeks), a medium-term fall (-100.0% over three months), and a longer-term loss (-98.18% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that ENvue Medical, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -27.27%, with price expected at $0.80 by May 28, 2026, within a range of $0.44 to $1.14 3-Month Outlook: Projected fall of -100.0%, reaching $0.00 by August 12, 2026, with a range of $0.00 to $0.10. 1-Year Outlook: Projected loss of -98.18%, with price at $0.02 by May 14, 2027, within a range of $0.00 to $0.11.